A comparison of netilmicin and tobramycin therapy in patients with renal impairment

Geoffrey J. Gorse, Jack M. Bernstein, Robert E. Cronin, Paul S. Etzell

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We evaluated the toxicity and efficacy of netilmicin and tobramycin in 89 older adults with serious bacterial infections and pre-existing renal impairment in a prospective, blinded, randomized trial. Complete resolution or improvement of infection occurred at 34/36 (94% evaluable sites in netilmicin-treated patients and at 26/31 (84% evaluable sites in tobramycin-treated patients. 10/44 (23% netilmicin- and 7/45 (16% tobramycin-treated patients experienced nephrotoxicity during treatment. The mean serum creatinine level improved significantly at the end of therapy compared to pre-treatment in those patients who did not experience nephrotoxicity in both treatment groups. 5/19 (26% netilmicin-treated patients and 2/18 (11% tobramycin-treated patients assessable for ototoxicity experienced decrements in auditory thresholds. Ototoxic netilmicin-treated patients had higher serum netilmicin levels than did non-ototoxic patients. Patients who experienced ototoxicity were not more likely to have experienced nephrotoxicity. The rates of toxicity were not statistically different and were similar to those seen in studies of patients with normal pre-treatment renal function

Original languageEnglish (US)
Pages (from-to)503-514
Number of pages12
JournalScandinavian Journal of Infectious Diseases
Volume24
Issue number4
DOIs
StatePublished - 1992

Fingerprint

Netilmicin
Tobramycin
Kidney
Therapeutics
Auditory Threshold
Serum
Bacterial Infections
Creatinine

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Immunology

Cite this

A comparison of netilmicin and tobramycin therapy in patients with renal impairment. / Gorse, Geoffrey J.; Bernstein, Jack M.; Cronin, Robert E.; Etzell, Paul S.

In: Scandinavian Journal of Infectious Diseases, Vol. 24, No. 4, 1992, p. 503-514.

Research output: Contribution to journalArticle

Gorse, Geoffrey J. ; Bernstein, Jack M. ; Cronin, Robert E. ; Etzell, Paul S. / A comparison of netilmicin and tobramycin therapy in patients with renal impairment. In: Scandinavian Journal of Infectious Diseases. 1992 ; Vol. 24, No. 4. pp. 503-514.
@article{d0b5483512034b25aadb56108cf82f88,
title = "A comparison of netilmicin and tobramycin therapy in patients with renal impairment",
abstract = "We evaluated the toxicity and efficacy of netilmicin and tobramycin in 89 older adults with serious bacterial infections and pre-existing renal impairment in a prospective, blinded, randomized trial. Complete resolution or improvement of infection occurred at 34/36 (94{\%} evaluable sites in netilmicin-treated patients and at 26/31 (84{\%} evaluable sites in tobramycin-treated patients. 10/44 (23{\%} netilmicin- and 7/45 (16{\%} tobramycin-treated patients experienced nephrotoxicity during treatment. The mean serum creatinine level improved significantly at the end of therapy compared to pre-treatment in those patients who did not experience nephrotoxicity in both treatment groups. 5/19 (26{\%} netilmicin-treated patients and 2/18 (11{\%} tobramycin-treated patients assessable for ototoxicity experienced decrements in auditory thresholds. Ototoxic netilmicin-treated patients had higher serum netilmicin levels than did non-ototoxic patients. Patients who experienced ototoxicity were not more likely to have experienced nephrotoxicity. The rates of toxicity were not statistically different and were similar to those seen in studies of patients with normal pre-treatment renal function",
author = "Gorse, {Geoffrey J.} and Bernstein, {Jack M.} and Cronin, {Robert E.} and Etzell, {Paul S.}",
year = "1992",
doi = "10.3109/00365549209052637",
language = "English (US)",
volume = "24",
pages = "503--514",
journal = "Infectious Diseases",
issn = "2374-4235",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - A comparison of netilmicin and tobramycin therapy in patients with renal impairment

AU - Gorse, Geoffrey J.

AU - Bernstein, Jack M.

AU - Cronin, Robert E.

AU - Etzell, Paul S.

PY - 1992

Y1 - 1992

N2 - We evaluated the toxicity and efficacy of netilmicin and tobramycin in 89 older adults with serious bacterial infections and pre-existing renal impairment in a prospective, blinded, randomized trial. Complete resolution or improvement of infection occurred at 34/36 (94% evaluable sites in netilmicin-treated patients and at 26/31 (84% evaluable sites in tobramycin-treated patients. 10/44 (23% netilmicin- and 7/45 (16% tobramycin-treated patients experienced nephrotoxicity during treatment. The mean serum creatinine level improved significantly at the end of therapy compared to pre-treatment in those patients who did not experience nephrotoxicity in both treatment groups. 5/19 (26% netilmicin-treated patients and 2/18 (11% tobramycin-treated patients assessable for ototoxicity experienced decrements in auditory thresholds. Ototoxic netilmicin-treated patients had higher serum netilmicin levels than did non-ototoxic patients. Patients who experienced ototoxicity were not more likely to have experienced nephrotoxicity. The rates of toxicity were not statistically different and were similar to those seen in studies of patients with normal pre-treatment renal function

AB - We evaluated the toxicity and efficacy of netilmicin and tobramycin in 89 older adults with serious bacterial infections and pre-existing renal impairment in a prospective, blinded, randomized trial. Complete resolution or improvement of infection occurred at 34/36 (94% evaluable sites in netilmicin-treated patients and at 26/31 (84% evaluable sites in tobramycin-treated patients. 10/44 (23% netilmicin- and 7/45 (16% tobramycin-treated patients experienced nephrotoxicity during treatment. The mean serum creatinine level improved significantly at the end of therapy compared to pre-treatment in those patients who did not experience nephrotoxicity in both treatment groups. 5/19 (26% netilmicin-treated patients and 2/18 (11% tobramycin-treated patients assessable for ototoxicity experienced decrements in auditory thresholds. Ototoxic netilmicin-treated patients had higher serum netilmicin levels than did non-ototoxic patients. Patients who experienced ototoxicity were not more likely to have experienced nephrotoxicity. The rates of toxicity were not statistically different and were similar to those seen in studies of patients with normal pre-treatment renal function

UR - http://www.scopus.com/inward/record.url?scp=0026688052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026688052&partnerID=8YFLogxK

U2 - 10.3109/00365549209052637

DO - 10.3109/00365549209052637

M3 - Article

C2 - 1411317

AN - SCOPUS:0026688052

VL - 24

SP - 503

EP - 514

JO - Infectious Diseases

JF - Infectious Diseases

SN - 2374-4235

IS - 4

ER -